When: Price reaches $375 (50 SMA)

Then: Higher-conviction reload at full trimmed amount

HOLD with 15-25% position trim; potential buy zone at 375-395

• AMGN has rallied 24.5% in five weeks to a closing print of 442.36, which is above the upper Bollinger band at 441.15
• RSI reading of 79.80 represents overbought conditions with historical risk of 15-25% pullbacks
• Forward P/E of 18.1x versus trailing P/E of 27.4x reflects 34% compression, largely pricing in MariTide success
• Stock has moved from 269 to 442.36 in twelve months, suggesting significant optimism already priced in
• Receivables grew 17.6% against 9.5% revenue growth, indicating potential working capital pressure
• Stop loss level at 375 represents approximately 15% downside from current levels
• Recommended trim of 15-25% locks in gains and reduces exposure to MariTide binary event
• Buy zone identified at 375-395 offers superior risk-reward for re-adding exposure
• Net debt of 43 billion with 2.5x leverage ratio limits flexibility to absorb adverse scenarios
• Debt reduced from 64.6 billion to 57 billion with interest coverage of 6.7x

→ vs aggressive: The aggressive analyst's RSI defense ignores historical instances where extended overbought readings preceded sharp 15-20% pullbacks within weeks

→ vs aggressive: The 37% DCF gap is model-dependent and sensitive to discount rate and terminal growth assumptions; multiple valuation methodologies showing mixed signals suggests the market is pricing in execution success rather than mispricing

→ vs aggressive: The trim recommendation is disciplined, not timid — it locks in gains and creates dry powder, which the risk committee would prefer over holding full size into a binary catalyst

→ vs aggressive: MariTide is not a free option — the 34% P/E compression reflects substantial earnings growth expectations already priced in, and Phase 3 data represents real binary risk that trimming addresses

→ vs aggressive: The Nvidia-Apple-Meta comparison is cherry-picking; momentum stocks like Tesla and Peloton had similar RSI readings before correcting 50%

HOLD; trim 10-15% into 441-444 zone; trailing stop around 410-420; buy zone 375-395

• RSI at 79.80 with close above upper Bollinger band indicates momentum intact but entry asymmetry has flipped
• 37% DCF gap combined with Q2 operating income growth of 32% YoY, 22 products growing double-digits, operating margin expansion from 24.7% to 35.5%
• 18.1x forward P/E is reasonable but not cheap; fair value for high-quality compounder in constructive setup
• MariTide success partially priced in but magnitude of successful Phase 3 readout not fully captured in current multiples; realistic scenario is modest rerating on positive, meaningful de-rating on negative
• Receivables build of 17.6% against 9.5% revenue growth is a real gap warranting monitoring; yellow flag if doesn't normalize over next two quarters
• Net debt to EBITDA of 2.5x with 6.7x interest coverage is investment-grade quality and improving
• AMGN fundamentals: $239B market cap, $8.6B trailing twelve-month free cash flow, 2.37% dividend yield, 17 billion-dollar franchises
• Recommended trailing stop around 410 based on 2x ATR of approximately $11, aligned with 10 EMA dynamic support at 418
• Buy zone of 375-395 (10 EMA at 418, 50 SMA at 375, swing zone at 395-400) offers better risk-reward than chasing current levels
• Macro backdrop constructive: Fed on hold, soft landing priced in, healthcare sector at record highs, rotation toward profitable drugmakers

→ vs aggressive: Momentum framing is seductive and confusing 'no divergence yet' with 'no risk of reversal' is a classic technical analysis mistake; dismissing overbought conditions at 79.80 RSI is confirmation bias

→ vs aggressive: Nvidia/Apple/Meta comparison is genuinely misleading—those names had multiple 20-40% pullbacks along their ascent, and smart investors added to pullbacks rather than chasing all-time highs

→ vs aggressive: Asymmetric upside framing for MariTide is incomplete; realistic scenario is modest rerating, not exponential, while negative readout could cause meaningful de-rating

→ vs conservative: 15-25% trim recommendation is too aggressive given MACD expanding, all three moving averages aligned bullishly, volume confirming, and no bearish divergence across most indicators

→ vs conservative: Peloton and SPAC comparisons are insulting to AMGN's fundamentals—a $239B mega-cap with $8.6B FCF and 2.37% dividend yield is fundamentally different from no-earnings momentum names

→ vs conservative: Bad case framing (MariTide disappointment plus recession plus refinancing pressure) is a tail scenario not appropriate for base-case position sizing

→ vs conservative: Receivables caution is valid but should be monitoring without overreacting; Q2 operating cash flow was strong at $4B